Allos Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of small molecule drugs for cancer treatments in the United States. The company has three product candidates in development: EFAPROXYN (efaproxiral), PDX (pralatrexate), and RH1. Its lead product, EFAPROXYN (efaproxiral), a synthetic small molecule designed to sensitize hypoxic, or oxygen-deprived, tumor tissue during radiation therapy is in phase III clinical program for brain metastases from breast cancer; Phase I clinical program for non small cell lung cancer with concurrent chemotherapy; and Phase 1b/2 clinical program for cervical cancer. The company’s PDX (pralatrexate), a...